Last reviewed · How we verify
Amodiaquine plus artesunate; Artekin
Amodiaquine plus artesunate; Artekin is a Small molecule drug developed by Menzies School of Health Research. It is currently in Phase 1 development.
At a glance
| Generic name | Amodiaquine plus artesunate; Artekin |
|---|---|
| Sponsor | Menzies School of Health Research |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children (PHASE3)
- A Randomised Trial of Artekin and Artesunate & Amodiaquine for Uncomplicated Malaria in Timika, Papua, Indonesia. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amodiaquine plus artesunate; Artekin CI brief — competitive landscape report
- Amodiaquine plus artesunate; Artekin updates RSS · CI watch RSS
- Menzies School of Health Research portfolio CI
Frequently asked questions about Amodiaquine plus artesunate; Artekin
What is Amodiaquine plus artesunate; Artekin?
Amodiaquine plus artesunate; Artekin is a Small molecule drug developed by Menzies School of Health Research.
Who makes Amodiaquine plus artesunate; Artekin?
Amodiaquine plus artesunate; Artekin is developed by Menzies School of Health Research (see full Menzies School of Health Research pipeline at /company/menzies-school-of-health-research).
What development phase is Amodiaquine plus artesunate; Artekin in?
Amodiaquine plus artesunate; Artekin is in Phase 1.